Use of Fibrates in the United States and Canada
Open Access
- 23 March 2011
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 305 (12) , 1217-1224
Abstract
Health care reform has generated interest in identifying strategies to decrease health care costs without depriving patients of the health benefits of evidence-based therapies and generic formulations of drugs.1-3 The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial recently showed that fenofibrate plus statins in patients with type 2 diabetes did not reduce cardiovascular events more than use of statins alone.4 The only other fenofibrate study, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), also failed to show reduced cardiovascular morbidity and mortality.5 These negative studies raise questions about a medication with more than $1 billion in sales in the United States.6Keywords
This publication has 21 references indexed in Scilit:
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysisThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Long-term trends in use of and expenditures for cardiovascular medications in CanadaCanadian Medical Association Journal, 2009
- International Prices And Availability Of Pharmaceuticals In 2005Health Affairs, 2008
- Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinThe American Journal of Cardiology, 2005
- Risk of adverse events with fibrates*The American Journal of Cardiology, 2004
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987